Astrazeneca annual operating cash flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Operating Cash Flow Growth & History (AZN)
Astrazeneca's operating cash flow was $14.57B for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $14.57B | $2.71B | +22.88% |
| 2024 | 2024-12-31 | $11.86B | $1.52B | +14.65% |
| 2023 | 2023-12-31 | $10.35B | $537.0M | +5.48% |
| 2022 | 2022-12-31 | $9.81B | $3.85B | +64.48% |
| 2021 | 2021-12-31 | $5.96B | $1.16B | +24.26% |
| 2020 | 2020-12-31 | $4.80B | $1.83B | +61.64% |
| 2019 | 2019-12-31 | $2.97B | $351.0M | +13.41% |
| 2018 | 2018-12-31 | $2.62B | −$960.0M | −26.83% |
| 2017 | 2017-12-31 | $3.58B | −$567.0M | −13.68% |
| 2016 | 2016-12-31 | $4.14B | $821.0M | +24.70% |
| 2015 | 2015-12-31 | $3.32B | — | — |
Astrazeneca quarterly operating cash flow
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.87B | −$521.0M | −15.39% |
| Q1 2026 | 2026-03-31 | $3.36B | — | — |
| Q4 2025 | 2025-12-31 | $2.34B | — | — |
| Q3 2025 | 2025-09-30 | $5.13B | — | — |
| Q2 2025 | 2025-06-30 | $3.39B | — | — |
Astrazeneca operating cash flow trends
Over the last five fiscal years, Astrazeneca's operating cash flow increased from $4.80B to $14.57B, a change of $9.78B. The latest reported quarter, Q2 2026, shows $2.87B.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...